In vivo evaluation and in vitro metabolism of leuprolide in mice - Mass spectrometry-based biomarker measurement for efficacy and toxicity

Journal of Mass Spectrometry

Volumn 43, Issue 10, 2008, Pages 1381-1392

  Sofianos, Zacharias D ^a   Katsila, Theodora ^a   Kostomitsopoulos, Nikolaos ^a   Balafas, Vaggelis ^a   Matsoukas, John ^b   Tselios, Theodoros ^b   Tamvakopoulos, Constantin ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Biomarker measurements; Mass spectrometry; Peptide metabolism; Peptide quantification; Pharmacokinetics

Indexed keywords

AMINES; ANIMAL CELL CULTURE; BIOCHEMISTRY; CHROMATOGRAPHIC ANALYSIS; CONTROLLED DRUG DELIVERY; ENZYME INHIBITION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; ION CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLISM; PEPTIDES; PHARMACOKINETICS; PLASMAS; PROTEINS; SPECTROMETERS; SPECTROMETRY; SPECTRUM ANALYSIS;

ACTIVE PEPTIDES; ANIMAL MODELS; BIOACTIVE PEPTIDES; ENDOGENOUS FACTORS; IN VITRO; IN VIVO EVALUATIONS; IN-VIVO; INTRAPERITONEAL ADMINISTRATIONS; LEUPROLIDE; LIMIT OF QUANTIFICATIONS; LINEAR ION TRAPS; MOUSE KIDNEYS; MOUSE MODELS; MOUSE PLASMAS; PEPTIDE DRUGS; PEPTIDE QUANTIFICATION; PHARMACOKINETIC PROPERTIES; PLASMA CONCENTRATIONS; PROSTATE CANCERS; QUADRUPOLE; QUANTITATIVE DETERMINATIONS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

LEUPRORELIN; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ION TRAP MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; CALIBRATION; FREEZING; INDICATORS AND REAGENTS; KIDNEY; LEUPROLIDE; MALE; MEMBRANES; MICE; MICE, INBRED C57BL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TESTOSTERONE;

ANIMALIA; MUS;

EID: 55249127332     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1416     Document Type: Article

References (42)

1. Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease: prostate cancer. The New England Journal of Medicine 2003; 349: 366.
2. Crawford ED, DeAntonio EP, Labrie F, Schroder FH, Geller J. Endocrine therapy of prostate-cancer: optimal form and appropriate timing. The Journal of Clinical Endocrinology and Metabolism 1995; 80: 1062.
3. Agarwal R. Cell signalling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochemical Pharmacology 2000; 60: 1051.
4. Labrie F. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. Journal of Andrology 2004; 25: 305.
5. Wells A, Souto JCS, Solava J, Kassis J, Bailey KJ, Turner T. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clinical Cancer Research 2002; 8: 1251.
6. Haviv F, Fitzpatrick TD, Nichols CJ, Swenson RE, Bush EN, Diaz G, Nguyen A, Nellans HN, Hoffman DJ, Ghanbari H, Johnson ES, Love S, Cybulski V, Greer J. Stabilization of the N-terminal residues of the luteinizing hormone-releasing hormone agonists and the effect on pharmacokinetics. Journal of Medicinal Chemistry 1992; 35: 3890.
7. Zheng Y, Fulu MY, Qiu Y, Reiland TL. Enzymatic degradation of leuprolide in rat intestinal mucosal homogenates. Pharmaceutical Development and Technology 1999; 4: 539.
8. Zheng Y, Qiu Y, Lu M, Hoffman D, Reiland TL. Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. International Journal of Pharmaceutics 1999; 185: 83.
9. Adjei A, Love S, Johnson E, Diaz G, Greer J, Haviv F, Bush E. Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. Journal of Drug Targeting 1993; 1: 251.
10. Sennello LT, Finley RA, Chu SY, Jaqst C, Max D, Rollins DE, Tolman KG. Single - dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. Journal of Pharmaceutical Sciences 1986; 75: 158.
11. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clinical Pharmacokinetics 2002; 41: 485.
12. Meyer BR, Kreis W, Eschbach J, O'Mara V, Rosen S, Sibalis D. Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clinical Pharmacology and Therapeutics 1990; 48: 340.
13. Okada H, Yamazaki I, Ogawa I, Hirai S, Yashiki T, Mima H. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement. Journal of Pharmaceutical Sciences 1982; 71: 1367.
14. Adjei A, Sundberg D, Miller J, Chun A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharmaceutical Research 1992; 9: 244.
15. Fulu MY, Lee D, Subba Rao G. Percutaneous absorption enhancement of leuprolide. Pharmaceutical Research 1992; 9: 1575.
16. Mazzei T, Mini E, Eandi M, Reali EF, Fioretto L, Bartoletti R, Rizzo M, Calabro G, Periti P. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic-cancer: a dose-response evaluation. Drugs Under Experimental and Clinical Research 1989; 15: 373.
17. Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clinical Therapeutics 2002; 11: 1902.
18. Ueno H, Matsuo S. High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite. Journal of Chromatography 1991; 566: 57.
19. Okada H, Inoue Y, Heya T, Ueno H, Ogawa Y, Toguchi H. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharmaceutical Research 1991; 8: 787.
20. Medeiros dos SM, Turner AJ, Ljungqvist AL, Folkers K. Metabolic stability of the LHRH antagonist antide to cell-surface peptidases. Biochemical and Biophysical Research Communications 1991; 176: 25.
21. De Kock SS, Rodgers JP, Swanepoel BC. Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. Rapid Communications in Mass Spectrometry 2001; 15: 1191.
22. Delinsky DC, Hill KT, White CA, Bartlett MG. Quantitative determination of the polypeptide motilin in rat plasma by externally calibrated liquid chromatography/electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry 2004; 18: 293.
23. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annual Review of Biochemistry 2001; 70: 437.
24. Tamvakopoulos C. Mass spectrometry for the quantitation of bioactive peptides in biological fluids. Mass Spectrometry Reviews 2007; 26: 389.
25. Szeto HH, Lovelace JL, Fridland G, Soong Y, Fasolo J, Wu D, Desiderio DM, Sciller PW. In vivo pharmacokinetics of selective μ - opioid peptide agonists. The Journal of Pharmacology and Experimental Therapeutics 2001; 298: 57.
26. Szeto HH, Clapp JF, Desiderio DM, Schiller PW, Grigoriants OO, Soong Y, Wu D, Olariu N, Tseng JL, Becklin R. In vivo disposition of dermorphin analog (DALDA) in nonpregnant and pregnant sheep. The Journal of Pharmacology and Experimental Therapeutics 1998; 284: 61.
27. Desiderio DM, Wirth U, Lovelace JL, Fridland G, Umstot ES, Nquyen TMD, Sciller PW, Szeto HH, Clapp JF. Matrix - assisted laser desorption/ionization mass spectrometric quantification of themu opioid receptor agonist DAMGO in ovine plasma. Journal of Mass Spectrometry 2000; 35: 725.
28. Wan H, Umstot ES, Szeto HH, Schiller PW, Desiderio DM. Quantitative analysis of [Dmt1]DALDA in ovine plasma by capillary liquid chromatography - nanospray ion - trap mass spectrometry. Journal of Chromatography B 2004; 803: 83.
29. Cukierski MJ, Johnson PA, Beck JC. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs. International Journal of Toxicology 2001; 20: 369.
30. Claasen V. Neglected Factors in Pharmacology and Neuroscience Research. Elsevier: Amsterdam, 1994.
31. Bonfiglio R, King RC, Olah TV, Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Communications in Mass Spectrometry 1999; 13: 1175.
32. Berger H, Heinrich N, Albrecht E, Kertscher U, Oehlke J, Bienert M, Schäfer H, Baeger I, Mehlis B. Gonadotropin-releasing hormone (GNRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. Regulatory Peptides 1991; 33: 299.
33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Analytical Biochemistry 1976; 72: 248.
34. Hopfgartner G, Husser C, Zell M. Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer. Journal of Mass Spectrometry 2003; 38: 138.
35. 3 quantitation for the analysis of pharmaceutical compounds in human plasma using chip-based infusion. Rapid Communications in Mass Spectrometry 2004; 18: 1995.
36. Brudel M, Kertscher U, Berger H, Mehlis B. Liquid chromatographic mass-spectrometric studies on the enzymatic degradation of gonadotropin- releasing hormone. Journal of Chromatography A 1994; 661: 55.
37. Copley K, McCowen K, Hiles R, Nielsen RL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Current Drug Metabolism 2006; 7: 367.
38. Anderes KL, Luthin DR, Castillo R, Kraynov EA, Castro M, Nared-Hood K, Gregory ML, Pathak VP, Christie LC, Paderes G, Vazir H, Ye Q, Anderson MB, May JM. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. The Journal of Pharmacology and Experimental Therapeutics 2003; 305: 688.
39. Li H, Anderes KL, Kraynov EA, Luthin DR, Do Q-Q, Hong Y, Tompkins E, Sun ET, Rajapakse R, Pathak VP, Christie LC, Vazir H, Castillo R, Gregory ML, Castro M, Nared-Hood K, Paderes G, Anderson MB. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. Journal of Medicinal Chemistry 2006; 49: 3362.
40. Motelica-Heino I, Castanier M, Corbier P, Edwards DA, Roffi J. Testosterone levels in plasma and testes of neonatal mice. Journal of Steroid Biochemistry 1988; 31: 283.
41. Lee TT, Cheng BH, Tsai EM, Yang CH, Chang Y, Li S, Lee JN. Chronic administration of atrial natriuretic peptide reduces testosterone production of testes in mice. Journal of Andrology 2003; 24: 912.
42. Mock EJ, Norton HW, Frankel AI. Daily rhythmicity of serum testosterone concentration in the male laboratory rat. Endocrinology 1978; 103: 1111.